Received May 19, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | UNK | — |
| MNP | MENINGOCOCCAL CONJUGATE (PENMENVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
Extremly sick; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of sickness in a adolescent male patient who received Men B NVS (Bexsero) for prophylaxis. Co-suspect products included Men ABCWY NVS (Penmenvy) for prophylaxis. On an unknown date, the patient received Bexsero and Penmenvy. On an unknown date, an unknown time after receiving Bexsero and Penmenvy, the patient experienced sickness (Verbatim: Extremly sick). The outcome of the sickness was resolved. The reporter considered the sickness to be related to Bexsero and Penmenvy. The reporter considered the sickness to be unrelated to Bexsero Pre-Filled Syringe Device and Penmenvy Pre-Filled Syringe Device. The company considered the sickness to be related to Bexsero and Penmenvy. The company considered the sickness to be unrelated to Bexsero Pre-Filled Syringe Device and Penmenvy Pre-Filled Syringe Device. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 12-MAY-2026 After receiving the first shot for this vaccine the reporter's son got extremely sick from it. It basically was giving him the meningitis symptoms. It was weeks until he was back to himself. It was extremely scary watching how sick he was. The batch number was not provided, and we are unable to contact the reporter.